Serum Progranulin Levels and Disease Activity in Patients with Axial Spondyloarthritis

Abstract Background Axial spondyloarthritides (ax-SpA) are a group of chronic systemic diseases of unknown aetiology, affecting mostly young men, with common features such as inflammatory low back pain, axial skeletal involvement, sacroiliitis, and association with HLA-B27. Inflammatory cytokines, mainly TNF-α, play a role in its aetiopathogenesis. Progranulin (PGRN) is thought to be an anti-inflammatory molecule that acts through the TNF-α pathway. In our study, we aimed to investigate the relationship between serum PGRN levels and disease activity in patients with AS. Material and Methods Forty-five patients between the ages of 18 and 65 who were classified as having ax-SpA according to ASAS classification criteria were included in our study. Forty-five individuals between the ages of 18 and 65 who did not have pregnancy or lactation status, no acute or chronic infection and no malignancy or rheumatic disease were included as the healthy control group. In addition, BASDAI, BASFI, BASMI, ASDAS-CRP, ESR and CRP levels were recorded in the patient group to determine the laboratory and clinical findings of patients with ax-SpA. Results Mean serum progranulin levels were higher in axial SpA patients compared with the control group (5156.72±1274.34 vs. 4836.50±1422.10), but this result was not statistically significant (p=0.275). Serum progranulin levels were negatively correlated with ESR (p=0.031) but ASDAS-CRP (p=0.407) and BASDAI (p=0.297) values were not correlated with the progranulin levels. Conclusion Although we found a negative correlation between progranulin and ESR, we did not find any association between progranulin and disease activity in patients with axSpA. There is a need for new and larger studies to be conducted with a higher number of participants in this patient group and to measure serum PGRN levels as well as antibodies against PGRN.

[1]  Shanzheng Wang,et al.  Distinctive roles of tumor necrosis factor receptor type 1 and type 2 in a mouse disc degeneration model , 2021, Journal of Orthopaedic Translation.

[2]  R. Ibrahim,et al.  Progranulin and beta‐catenin in psoriasis: An immunohistochemical study , 2019, Journal of cosmetic dermatology.

[3]  A. Hettinghouse,et al.  Progranulin: A conductor of receptors orchestra, a chaperone of lysosomal enzymes and a therapeutic target for multiple diseases. , 2019, Cytokine & growth factor reviews.

[4]  A. Hettinghouse,et al.  Targeting tumor necrosis factor receptors in ankylosing spondylitis , 2018, Annals of the New York Academy of Sciences.

[5]  H. Marzo-Ortega,et al.  New advances in the understanding and treatment of axial spondyloarthritis: from chance to choice , 2018, Therapeutic advances in chronic disease.

[6]  Y. Tada,et al.  Progranulin Overproduction Due to Fli‐1 Deficiency Contributes to the Resistance of Dermal Fibroblasts to Tumor Necrosis Factor in Systemic Sclerosis , 2015, Arthritis & rheumatology.

[7]  R. Palfree,et al.  The Evolution of the Secreted Regulatory Protein Progranulin , 2015, PloS one.

[8]  J. Hayashi,et al.  Increased Serum GP88 (Progranulin) Concentrations in Rheumatoid Arthritis , 2014, Inflammation.

[9]  M. Pfreundschuh,et al.  Progranulin antibodies in autoimmune diseases. , 2013, Journal of autoimmunity.

[10]  Chuanju Liu,et al.  Insights into the role of progranulin in immunity, infection, and inflammation , 2013, Journal of leukocyte biology.

[11]  K. Akashi,et al.  Serum progranulin levels are elevated in patients with systemic lupus erythematosus, reflecting disease activity , 2012, Arthritis Research & Therapy.

[12]  S. Cheung,et al.  Granulin-Epithelin Precursor Is an Oncofetal Protein Defining Hepatic Cancer Stem Cells , 2011, PloS one.

[13]  Chuan-ju Liu.  Progranulin: A promising therapeutic target for rheumatoid arthritis , 2011, FEBS letters.

[14]  Zhinan Yin,et al.  The Growth Factor Progranulin Binds to TNF Receptors and Is Therapeutic Against Inflammatory Arthritis in Mice , 2011, Science.

[15]  M. Dougados,et al.  The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general , 2010, Annals of the rheumatic diseases.

[16]  M. Dougados,et al.  The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal , 2009, Annals of the rheumatic diseases.

[17]  M. Fasshauer,et al.  Serum Progranulin Concentrations May Be Associated With Macrophage Infiltration Into Omental Adipose Tissue , 2009, Diabetes.

[18]  M. Dougados,et al.  Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis , 2008, Annals of the rheumatic diseases.

[19]  J. Braun,et al.  Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor α in two patients with early disease and transforming growth factor β in three more advanced cases , 2005, Annals of the rheumatic diseases.

[20]  Liang Cheng,et al.  PC Cell-Derived Growth Factor Expression in Prostatic Intraepithelial Neoplasia and Prostatic Adenocarcinoma , 2004, Clinical Cancer Research.

[21]  D. MacEwan.  TNF receptor subtype signalling: differences and cellular consequences. , 2002, Cellular signalling.

[22]  A. Bateman,et al.  Cellular Localization of Gene Expression for Progranulin , 2000, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[23]  R. Hrabal,et al.  The hairpin stack fold, a novel protein architecture for a new family of protein growth factors , 1996, Nature Structural Biology.

[24]  A. Calin,et al.  A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. , 1994, The Journal of rheumatology.

[25]  A. Calin,et al.  A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. , 1994, The Journal of rheumatology.

[26]  A Calin,et al.  Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. , 1994, The Journal of rheumatology.

[27]  G. Plowman,et al.  The epithelin precursor encodes two proteins with opposing activities on epithelial cell growth. , 1992, The Journal of biological chemistry.

[28]  R. Palfree,et al.  Isolation and sequence of the granulin precursor cDNA from human bone marrow reveals tandem cysteine-rich granulin domains. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[29]  C. Maury,et al.  Tumor necrosis factor in the serum of patients with systemic lupus erythematosus. , 1989, Arthritis and rheumatism.

[30]  A. Cats,et al.  Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. , 1984, Arthritis and rheumatism.

[31]  A. Hettinghouse,et al.  Progranulin: A key player in autoimmune diseases. , 2018, Cytokine.

[32]  Chuan-ju Liu,et al.  Progranulin: a growth factor, a novel TNFR ligand and a drug target. , 2012, Pharmacology & therapeutics.

[33]  S. Schreiber,et al.  Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. , 1993, Clinical and experimental immunology.